This 5-question survey of 30 primary care physicians and 29 endocrinologists in the United States evaluates the impact of the EMPA-REG cardiovascular outcomes trial (CVOT) of SGLT2 inhibitor Jardiance (Boehringer, LLY). The survey looks at what subpopulations Jardiance is likely to be used in, as well as whether Jardiance would be added instead of a competitor or switched in place of one. The survey also gives projected usage of Jardiance and competitors prior to and after the CVOT results from other SGLT2 inhibitors.

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2015 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

To purchase this survey, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.